Finanzas de ImageneBio Inc (IMA)IMAImageneBio Inc

Evaluating the bottom line, ImageneBio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -41.34%, provide a clear picture of how effectively IMA converts its operational activities into shareholder value.

In the context of the broader market, IMA competes directly with industry leaders such as LONA and MREO. With a market capitalization of $46.59M, it holds a leading position in the sector. When comparing efficiency, IMA's gross margin of N/A stands against LONA's N/A and MREO's N/A. Such benchmarking helps identify whether ImageneBio Inc is trading at a premium or discount relative to its financial performance.

The company has shown substantial losses, with a net income of -25.6 million in Q3 2025 and a gross margin of 100% in Q1 2025, but no revenue in subsequent quarters, indicating volatility in financial performance.